Gopinath Nagaraj | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Gopinath Nagaraj | Pharmacology | Best Researcher Award

University of Madras | India

Dr. Gopinath Nagaraj is an accomplished biochemist and molecular biologist specializing in cardiovascular research, with a particular focus on elucidating the molecular mechanisms underlying cardiac hypertrophy and heart failure. He earned his Ph.D. in Biochemistry from the University of Madras under the mentorship of Prof. Elangovan Vellaichamy, where his doctoral research explored the intricate molecular pathways governing cardiac hypertrophy through both in vitro and in vivo models. His expertise encompasses a wide range of cellular and molecular biology techniques, including qPCR, Western blotting, ELISA, FACS analysis, and fluorescence microscopy, all of which he has skillfully applied to investigate receptor signaling mechanisms and molecular cardiology.Dr. Gopinath’s pioneering research centers on the natriuretic peptide receptor-A (NPR-A/GC-A) signaling pathway and its modulation in cardiovascular physiology. His studies provide valuable insights into how NPR-A expression, internalization, and trafficking dynamics regulate receptor function and contribute to cardiovascular homeostasis. Through his innovative integration of experimental and computational methods—such as molecular docking and receptor trafficking assays—he has advanced understanding of how natural compounds like curcumin modulate receptor function and restore cellular signaling in stress-induced cardiac hypertrophy and inflammation models. This approach bridges receptor biology with natural product pharmacology, opening new therapeutic possibilities for cardiovascular disease management.His notable publications include Triiodo-L-thyronine Downregulates Npr1 Gene Transcription in H9c2 Cells: Involvement of β-AR-ROS Signaling published in Endocrine; C-Type Natriuretic Peptide Induces Cell Death and Sensitizes the Effect of Cisplatin in Human Non-Small Cell Lung Cancer Cells in International Journal of Peptide Research and Therapeutics; CNP Inhibits T3-Induced Hypertrophic Growth in H9c2 Cells: Impact of HDAC Inhibitor in Archives of Biochemistry and Biophysics; Curcumin with ANP Treatment Enhances the Internalization and Trafficking of NPR-A Mediated Signaling Pathway in Tissue and Cell; and Epigenetic Modulation of Natriuretic Peptide Receptor Signaling by HDAC Inhibitors in Thyroxine-Induced Cardiac Hypertrophy submitted to the European Journal of Pharmacology. Dr. Gopinath has contributed expert consultancy in receptor signaling and preclinical molecular evaluation for bioactive compounds, polymers, and nanoparticles with cardioprotective, anticancer, and anti-inflammatory properties. With multiple ongoing research projects, five publications in high-impact journals, and an h-index of three, he continues to strengthen the translational link between molecular cardiology and therapeutic innovation. His role as a reviewer for Discover Oncology further reflects his commitment to upholding scientific integrity and excellence in biomedical research. Through his innovative research, multidisciplinary collaborations, and translational insights, Dr. Gopinath exemplifies scientific dedication in advancing cardiovascular and molecular biosciences.

Profile: Google Scholar

Featured Publications

Elumalai, M., Nagaraj, G., Kasthuri, J., Vellaichamy, E., & Rajendiran, N. Evaluation of cytotoxic activity against A549 human lung cancer cells using green synthesized N-Cholyl D-Penicillamine encapsulated silver and gold nanoparticles. Inorganic Chemistry Communications, 153, 110834.

Baskaran, A., Elumalai, M., Nagaraj, G., Vellaichamy, E., & Rajendiran, N. Mucoadhesive and drug release of cholic acid-based thiomeric micelles and encapsulated silver and gold nanoparticles for anticancer studies. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 703, 135363.

Nagaraj, G., Dhanusu, S., Nachiappan, D. M., & Vellaichamy, E. C-type natriuretic peptide (CNP) induces cell death and sensitizes the effect of cisplatin in human non-small cell lung cancer cells (A549). International Journal of Peptide Research and Therapeutics, 28(4), 112.

Nagaraj, G., & Vellaichamy, E. Triiodo-L-thyronine (T3) downregulates Npr1 gene (coding for natriuretic peptide receptor-A) transcription in H9c2 cells: involvement of β-AR-ROS signaling. Endocrine, 85(3), 1075–1090.

Nagaraj, G., & Vellaichamy, E. CNP inhibits T3-induced hypertrophic growth in H9c2 cells: Impact of HDAC inhibitor. Archives of Biochemistry and Biophysics, 110648.

Elumalai, M., Nagaraj, G., Ramaraj, S. G., Vellaichamy, E., Tabata, H., & Rajendiran, N. NCPA-templated red-emitting gold nanoclusters: a turn-off-on fluorescent probe for rapid and selective detection of Cu²⁺ ions in live cells and evaluation of biological applications. Dalton Transactions (Cambridge, England: 2003).

Nagendra G-Drug Discovery and Development-Best Researcher Award-1013

Published on by Top Pharmaceutical

Dr. Nagendra G-Drug Discovery and Development-Best Researcher Award

REVA University-India

Author Profile `

Early Academic Pursuits

Dr. Nagendra Govindappa embarked on his academic journey with a strong inclination towards chemistry, which led him to pursue a Ph.D. at Bangalore University under the mentorship of Dr. V. V. Sureshbabu. His doctoral research focused on the design and synthesis of novel peptidomimetics and related intermediates. Noteworthy achievements during this period include the insertion of thioamide linkage into peptide backbones and the synthesis of isoselenocyanates for the development of selenourea peptidomimetics. These endeavors laid the groundwork for his subsequent contributions to the field of peptide chemistry.

Professional Endeavors

Following his doctoral studies, Dr. Nagendra Govindappa continued his academic journey as an Associate Professor at REVA University, Bangalore. He expanded his research horizons through collaborations with esteemed institutions such as CSIR-IICT, Hyderabad, and TUD, Germany. His tenure at these institutions further enriched his expertise in synthetic chemistry, natural product synthesis, and chemical biology. Notable projects include the total synthesis of Cyclosporin-O, development of one-pot protocols for glycopeptide synthesis, and the synthesis of anti-cancer agents targeting EGFR family proteins.

Contributions and Research Focus

Dr. Nagendra Govindappa's research primarily revolves around the design, synthesis, and evaluation of peptides and peptidomimetics with diverse functionalities. He has pioneered the incorporation of various heterocycles such as oxadiazole, thiadiazole, tetrazole, and thiopeptides into peptide scaffolds, thereby expanding the chemical space of peptidomimetics. His innovative approaches have enabled the synthesis of bioactive molecules with potential applications in drug discovery and material science. Currently, he is focused on the total synthesis of natural peptides using advanced synthetic strategies and nanocatalysis.

Accolades and Recognition

Dr. Nagendra Govindappa's contributions to the field of peptide chemistry have garnered widespread recognition. He has published over 30 research articles in reputed journals, including notable contributions to journals with high impact factors. His research has been cited extensively, as evidenced by his impressive h-index of 12. Additionally, he holds two patents, underscoring the innovative nature of his work. His editorial appointments and professional memberships further signify his standing in the scientific community.

Impact and Influence on Drug Discovery and Development

Dr. Nagendra Govindappa's research has made significant contributions to the synthesis and functionalization of peptides and peptidomimetics. His work has not only expanded the synthetic toolbox available to chemists but has also provided insights into the structure-activity relationships of bioactive molecules. Moreover, his collaborations with international research groups have facilitated knowledge exchange and fostered scientific advancements on a global scale. His efforts have thus had a profound impact on the fields of chemistry and pharmaceutical sciences.

Following successful identification and optimization of lead compounds, the most promising candidates progress to preclinical development, where they undergo rigorous testing in laboratory and animal models to evaluate their safety and efficacy profiles. If a candidate demonstrates favorable results in preclinical studies, it advances to clinical development, which consists of a series of human trials designed to assess its safety, efficacy, and dosage regimen. Clinical trials are conducted in multiple phases, starting with small-scale Phase I trials to evaluate safety in healthy volunteers, followed by Phase II trials to assess efficacy and optimal dosage in patients with the target condition, and finally, Phase III trials to confirm safety and efficacy in larger patient populations. Upon successful completion of clinical trials, regulatory approval is sought, and if granted, the drug can be introduced to the market, where ongoing post-marketing surveillance ensures its continued safety and effectiveness.

Legacy and Future Contributions

As Dr. Nagendra Govindappa continues his academic journey, his legacy is poised to endure through his impactful research and mentorship. His innovative approaches to peptide synthesis and his dedication to advancing the frontiers of chemical biology serve as an inspiration to aspiring scientists. Moving forward, he aims to further explore the potential of peptidomimetics in drug discovery and materials science while nurturing the next generation of researchers through mentorship and collaboration. His unwavering commitment to scientific excellence ensures that his contributions will continue to shape the landscape of chemical research for years to come.

Drug discovery and development is a complex and multifaceted process aimed at identifying, synthesizing, and bringing to market new medications to address unmet medical needs or improve upon existing treatments. The process typically begins with target identification, where scientists pinpoint specific molecules, proteins, or pathways involved in a disease process that could serve as potential therapeutic targets. Once a target is identified, researchers embark on the drug discovery phase, which involves screening large libraries of compounds to find molecules that interact with the target in a desired way. This phase often employs techniques such as high-throughput screening and computer-aided drug design to identify promising lead compounds, which undergo further optimization to enhance their potency, selectivity, and pharmacokinetic properties.

Notable Publication